 PHASE II STUDY AIMING TO EVALUATE THE EFFICACY AND SAFETY OF NILOTINIB PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS GIST RESISTANT OR INTOLERANT TO IMATINIB AND OR TO 2ND LINE TYROSINE KINAS TK INHIBITOR: 